The Richmond company (Nasdaq: BIOA) will get a fraction of the money upfront from Novartis (NYSE: NVS) — up to $20 million, ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat ...

What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...

Pfizer’s financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a "Buy" ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

In the most recent trading session, Eli Lilly (LLY) closed at $778.62, indicating a -0.05% shift from the previous trading day.

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...

The Village of Pleasant Prairie Plan Commission on Monday approved the preliminary site and operational plans for the ...